Koers Peregrine Pharmaceuticals Nasdaq
Aandelen
US7136613046
Farmaceutische producten
Omzet 2024 * | 139 mln. 128 mln. | Omzet 2025 * | 164 mln. 151 mln. | Marktkapitalisatie | 579 mln. 533 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -20 mln. -18,4 mln. | Nettowinst (verlies) 2025 * | -11 mln. -10,12 mln. | EV/omzet 2024 * | 4,16 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 3,53 x |
K/w-verhouding 2024 * |
-28,7
x | K/w-verhouding 2025 * |
-48,6
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 98,93% |
Recentste transcriptie over Peregrine Pharmaceuticals
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Nicholas Green
CEO | Chief Executive Officer | 60 | 30-07-20 |
Daniel Hart
DFI | Director of Finance/CFO | 50 | 01-08-18 |
Nick Ferguson
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-99 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gregory Sargen
BRD | Director/Board Member | 59 | 27-11-17 |
Joseph Carleone
CHM | Chairman | 78 | 27-11-17 |
Catherine Mackey
BRD | Director/Board Member | 68 | 25-07-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-2,32% | 90,45 mld. | |
+3,68% | 41,45 mld. | |
-10,90% | 33,57 mld. | |
+58,05% | 25,73 mld. | |
-19,56% | 14,73 mld. | |
-9,06% | 12,82 mld. | |
-11,34% | 11,7 mld. | |
-43,53% | 11,44 mld. | |
+3,75% | 8,79 mld. |